Cross-agency comparison: 🇪🇺 EMA leads with 73 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

This cross-agency pattern suggests the EMA is currently the most active and potentially the most procedurally dynamic environment, with MHRA and FDA also generating a meaningful but lower volume of output, while Health Canada appears comparatively quieter. Sponsors should consider that the higher cadence in Europe may indicate faster-moving expectations, more frequent interpretive shifts, and a greater need to monitor guidance updates closely, whereas global filing strategy may benefit from prioritizing EU intelligence and aligning core dossiers early to avoid region-specific rework. Resource planning could therefore favor a heavier regulatory surveillance and submission-readiness allocation for Europe, with enough flexible capacity to absorb parallel updates from the US and UK without fragmenting the global dossier strategy.